EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Human Retinal Organoid Modeling Defines Developmental Window and Therapeutic Vulnerabilities in MYCN-Amplified Retinoblastoma

Jinkyu Park, Gang Cui iD, Jiyun Hong, Han Jeong, Minseok Han iD, Min Seok Choi, Jeong Ah Lim, Sanguk Han iD, Christopher Seungkyu Lee, Min Kim iD, Sangwoo Kim iD, Junwon Lee iD und 1 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jinkyu Park und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Severance Eye Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul 03722, Republic of Ko…. Hauptthemen laut MEDLINE: Retinoblastoma, N-Myc Proto-Oncogene Protein, Organoids, Retina. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yonsei University College of Medicine (Faculty Research Grant), National Research Foundation of Korea (NRF) - Ministry of Science and ICT (MSIT), National Research Foundation of Korea (NRF) - Korea government (MSIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MYCN amplification without concurrent RB1 mutations characterizes a rare yet highly aggressive subtype of retinoblastoma; however, its precise developmental origins and therapeutic vulnerabilities remain incompletely understood. Here, we modeled this subtype by lentiviral-mediated MYCN overexpression in human pluripotent stem cell-derived retinal organoids, revealing a discrete developmental window (days 70–120) during which retinal progenitors showed heightened susceptibility to transformation. Tumors arising in this period exhibited robust proliferation, expressed SOX2, and lacked CRX, consistent with origin from primitive retinal progenitors. MYCN-overexpressing organoids generated stable cell lines that reproducibly gave rise to MYCN-driven tumors when xenografted into immunodeficient mice. Transcriptomic profiling demonstrated that MYCN-overexpressing organoids closely recapitulated molecular features of patient-derived MYCN-amplified retinoblastomas, particularly through activation of MYC/E2F and mTORC1 signaling pathways. Pharmacological screening further identified distinct therapeutic vulnerabilities, demonstrating distinct subtype-specific sensitivity of MYCN-driven cells to transcriptional inhibitors (THZ1, Flavopiridol) and the cell-cycle inhibitor Volasertib, indicative of a unique oncogene-addicted state compared to RB1-deficient retinoblastoma cells. Collectively, our study elucidates the developmental and molecular mechanisms underpinning MYCN-driven retinoblastoma, establishes a robust and clinically relevant human retinal organoid platform, and highlights targeted transcriptional inhibition as a promising therapeutic approach for this aggressive pediatric cancer subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoblastomaN-Myc Proto-Oncogene ProteinOrganoidsRetinaGene AmplificationRetinal NeoplasmsHumansAnimalsMiceCell Line, TumorSignal Transduction

Stichwörter der Autor:innen

MYCN amplificationprecision medicineretinal organoidsretinal progenitorretinoblastomatumorigenesis

Substanzen

N-Myc Proto-Oncogene ProteinMYCN protein, human

Autor:innen und Institutionen

  • Department of Ophthalmology, Severance Eye Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Department of Biomedical Systems Informatics, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Brain Korea 21 Project for Medical Science, Yonsei University, Seoul 03722, Republic of Korea.
  • Department of Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Department of Ophthalmology, Institute of Vision Research, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea.

ORCID-Profile: Gang Cui, Minseok Han, Sanguk Han, Min Kim, Sangwoo Kim, Junwon Lee

Förderung

  • Yonsei University College of Medicine (Faculty Research Grant)
  • National Research Foundation of Korea (NRF) - Ministry of Science and ICT (MSIT)
  • National Research Foundation of Korea (NRF) - Korea government (MSIT)
  • National Research Foundation of Korea (NRF) - Korea government (MSIT
  • Gene Editing-Control-Restoration Based Research Program - Korea government (MSIT)
  • National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT
  • National Research Foundation of Korea (NRF)
  • Gene Editing–Control–Restoration Based Research Program

Zitieren

APA

Park, J., Cui, G., Hong, J., Jeong, H., Han, M., Choi, M. S., Lim, J. A., Han, S., Lee, C. S., Kim, M., Kim, S., Lee, J., & Byeon, S. H. (2025). Human Retinal Organoid Modeling Defines Developmental Window and Therapeutic Vulnerabilities in MYCN-Amplified Retinoblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178675

Vancouver

Park J, Cui G, Hong J, Jeong H, Han M, Choi MS, et al. Human Retinal Organoid Modeling Defines Developmental Window and Therapeutic Vulnerabilities in MYCN-Amplified Retinoblastoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178675

BibTeX
@article{Park2025,
  author = {Park, Jinkyu and Cui, Gang and Hong, Jiyun and Jeong, Han and Han, Minseok and Choi, Min Seok and Lim, Jeong Ah and Han, Sanguk and Lee, Christopher Seungkyu and Kim, Min and Kim, Sangwoo and Lee, Junwon and Byeon, Suk Ho},
  title = {Human Retinal Organoid Modeling Defines Developmental Window and Therapeutic Vulnerabilities in MYCN-Amplified Retinoblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178675}
}
Kostenlos starten →